Home » Stocks » Aptinyx

Aptinyx Inc. (APTX)

Stock Price: $2.97 USD -0.01 (-0.34%)
Updated Oct 27, 2020 4:00 PM EDT - Market closed
After-hours: $3.09 +0.12 (4.04%) Oct 27, 6:45 PM

Stock Price Chart

Key Info

Market Cap 139.48M
Revenue (ttm) 3.16M
Net Income (ttm) -55.80M
Shares Out 46.96M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 27, 2020
Last Price $2.97
Previous Close $2.98
Change ($) -0.01
Change (%) -0.34%
Day's Open 3.08
Day's Range 2.91 - 3.09
Day's Volume 1,065,691
52-Week Range 1.60 - 6.47

More Stats

Market Cap 139.48M
Enterprise Value 23.42M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 46.96M
Float 23.76M
EPS (basic) -1.46
EPS (diluted) -1.42
FCF / Share -1.04
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 1.04M
Short Ratio 5.64
Short % of Float 4.37%
Beta 1.21
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 44.11
PB Ratio 1.27
Revenue 3.16M
Operating Income -57.34M
Net Income -55.80M
Free Cash Flow -47.53M
Net Cash 116.06M
Net Cash / Share 2.47
Gross Margin -1,285.93%
Operating Margin -1,813.47%
Profit Margin -1,764.50%
FCF Margin -1,503.26%
ROA -28.49%
ROE -46.04%
ROIC -5,078.00%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (9)

Buy 8
Overweight 0
Hold 1
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(275.08% upside)
Current: $2.97
Target: 11.14
*Average 12-month price target from 7 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth-44.19%32.49%-49.33%-
Gross Profit3.676.574.969.79
Operating Income-59.61-54.89-32.23-17.72
Net Income-57.41-53.28-32.07-15.48
Shares Outstanding33.5620.205.204.90
Earnings Per Share-1.71-2.64-6.17-3.16
Operating Cash Flow-52.09-47.45-32.74-19.72
Capital Expenditures-0.04-0.41-1.58-0.37
Free Cash Flow-52.13-47.86-34.31-20.09
Cash & Equivalents99.0315192.1416.95
Net Cash / Debt99.0315192.1416.95
Book Value101149-39.72-8.55
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Aptinyx Inc.
Country United States
Employees 43
CEO Norbert G. Riedel

Stock Information

Ticker Symbol APTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: APTX
IPO Date June 21, 2018


Aptinyx, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc to develop a compound for the treatment of major depressive disorder. Aptinyx Inc. was founded in 2015 and is headquartered in Evanston, Illinois.